Genotype‐guided antiplatelet treatment bests conventional therapy in averting MACE, MI
In patients with coronary artery disease or undergoing percutaneous coronary intervention, genotype-guided antiplatelet treatment may reduce the risk of major adverse cardiovascular events (MACE), stent thrombosis, and myocardial infarction (MI) without increasing the risk of bleeding over a long follow-up period, results of a recent study have shown.
